Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. - Wikidata - awgldk - TriplyDB

Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

http://www.wikidata.org/entity/Q36680199

about

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy Development of cell-cycle checkpoint therapy for solid tumors Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Development of synthetic lethality anticancer therapeutics.New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis.Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity.Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.Cell cycle proteins as promising targets in cancer therapy Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms.Emerging cell cycle inhibitors for acute myeloid leukemia.Targeting the ATR-CHK1 Axis in Cancer Therapy Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss.Upregulation of the ATR-CHEK1 pathway in oral squamous cell carcinomas.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.Studies of lncRNAs in DNA double strand break repair: what is new?ATR/CHK1 inhibitors and cancer therapy.Directing the use of DDR kinase inhibitors in cancer treatment.Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.

P2860

Q26745686-41DD8F50-7C1C-45A6-A192-5238662D5FE0 Q26781187-D267ABAE-9EB0-47CF-B996-47F883F196DF Q26863501-A9D3B4A7-1BB6-4410-8BAA-43E38F10F8AF Q26864870-7AE9B2A0-9349-46B0-B543-2C481E4340A9 Q28078268-3EEEFC01-30E7-48B5-893C-892D5E7CBDC9 Q28289090-C832BDC3-7C61-4CD3-88A9-7B2F3A4E6B22 Q33983255-B4AF455E-CB20-44DF-84E8-49BB90432760 Q34380368-C14C7798-0610-425A-B62E-EA51BD4FAE0C Q34715598-B5A89325-45A8-4944-98B5-EBD032D0573E Q35048469-23EDBCCB-2913-4BA1-83B5-68E9AE3DBAA4 Q35073758-B0AA6BF1-943F-4940-9B76-E17E813DFB58 Q35201518-8CDD5CC2-7136-4107-A6EE-427E548CE142 Q35740025-FA067F1B-659D-4562-B919-80D86E1E0322 Q35800291-A2137019-00EB-43EB-818E-454CDEEC7E45 Q36075291-AA8115F1-FBFC-4487-A3C5-1A204F52AEE0 Q36255484-B9E3D388-B04A-4496-86FC-F5640DD11C0B Q36413964-616B7B8C-27B7-45C7-B8F4-1901DC3AC48C Q36437713-A6D096A8-8200-4C75-885B-BE9274B89C95 Q36546469-42F77438-4C21-47DF-9F21-A3D5A7040EA5 Q36738836-0CE9EA23-BEB5-4705-885F-712EA4E22D7E Q36771796-985D8513-AB01-4D6A-AB44-AC43BF58832E Q37579567-5C7666E5-77C4-42E8-90B9-A5F515ECA34C Q37634102-0D35A019-4F1F-4C27-B0BE-DF633837B6EA Q37676283-17F7F021-F631-49E8-B596-BE6F4E3AA862 Q37693690-679BE524-013C-4F49-B51D-B7BAD6389578 Q38268221-6EA0FD3E-F149-40B0-88B5-6CA76297EF5F Q38785380-8714C7EE-C247-45DE-A908-20B524A5778B Q38817102-0A76BCC5-B63B-48EA-A85A-3BBAE7B96CE1 Q39044559-2B831277-2749-44EF-951F-7A25D5C60C6A Q39076159-11A7BC3B-21F7-4DF0-8894-6BDC2EA267C5 Q39175665-DCB2B048-B76C-431C-ACF0-C917DE60CF88 Q39540757-E1F81A7E-5944-4492-9EE0-08899ED9DCD7 Q39643726-96F59874-F707-44E2-8760-F30ACDA509AD Q41470356-7A5385B7-F227-43D5-963D-4806BEB35817 Q41838038-AE826A7D-7901-41CA-BB7A-24F919E25DC3 Q44601913-80A7F3DD-A85B-4144-BAE4-39123C7ABA93 Q46237274-5830B19C-C865-4AD0-8A3A-8B8E2E0679C2 Q47622968-77DB7184-E0B3-4AFB-9094-487450AED67F Q47687840-031DB6C3-24BC-4499-B937-C455E78BE2C7 Q47730914-BBBDBAA6-1BF8-4944-ACF5-035437DF2AB9

P2860

Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

http://www.wikidata.org/entity/Q36680199

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Phase I and pharmacologic tria ...... in refractory acute leukemias.

@ast

Phase I and pharmacologic tria ...... in refractory acute leukemias.

@en

type

label

Phase I and pharmacologic tria ...... in refractory acute leukemias.

@ast

Phase I and pharmacologic tria ...... in refractory acute leukemias.

@en

prefLabel

Phase I and pharmacologic tria ...... in refractory acute leukemias.

@ast

Phase I and pharmacologic tria ...... in refractory acute leukemias.

@en

P1433

Q36680199-A5AFD6A2-D5D5-447E-A6D0-958E66C68819

P1476

Q36680199-55FB9714-28CB-425B-A55E-82FB5E8A8B05

P2093

Q36680199-05747984-1B23-4741-A7DA-5805EB30B656

Q36680199-0A22346E-7AB6-4213-A9DE-25BACDB65081

Q36680199-0CBE1536-6F18-4F55-A006-67DC5CBF7A5C

Q36680199-173367CE-A705-46BB-9FCD-B40C87E9690A

Q36680199-1DAD2877-7607-45DF-AC8C-D0B1592D5CAE

Q36680199-33E01CA8-2B7D-4DFC-BBAD-2DA7B661FC4C

Q36680199-3A953FE3-6E14-410C-BF68-C6E98147A8B2

Q36680199-69276D18-FC1D-47CB-BDD2-9F0D3E0B8D3C

Q36680199-8BFB255C-D7B5-4BE7-AB28-4538163A29D3

Q36680199-8CA2B453-1B0E-41E3-8F35-335F19A96B9E

P2860

Q36680199-1D473CEC-2112-46A2-BF19-4CFD4AD6F7CE

Q36680199-1FCB0DE5-D613-4723-8AC3-60D4C306E76D

Q36680199-27FBBF14-1A20-46B6-AD75-58B133AAC2B6

Q36680199-2A3803DC-DD1D-43F1-A0B1-A49DF1E2D0A6

Q36680199-48C349FD-EE60-4AED-B0C7-698DE0C75B2B

Q36680199-53B8D990-2FD9-49FC-A8CA-E9ACA60C216D

Q36680199-5485CD21-9C0F-4F23-BE74-AE8F86BFA421

Q36680199-56FFDD62-5CF1-4E51-8198-D1C6F6F302BA

Q36680199-60C7E20C-AF44-4D2B-94CC-8488E8FFC1EF

Q36680199-6C28EF37-513D-4D2E-9F92-A770FC0E8471

P304

Q36680199-F286DD87-DF3D-4188-A3C7-DE6FD5ED8A10

P31

Q36680199-B798F362-2253-4DC6-879C-C66B08363596

P356

Q36680199-6E76BA19-2E36-49B3-BB6A-886E4975A23E

P407

Q36680199-20BD02C9-CCEC-407B-998A-62FCE5FD0E3A

P433

Q36680199-4F7F95B3-44AD-47C5-9F4D-0A5FBDBF575D

P478

Q36680199-C1A99DF3-7675-4612-A56E-56B381DB3071

P50

Q36680199-6893B274-B088-400B-B89F-F0C052330FB5

P577

Q36680199-53591C3A-3F1C-4AEB-A16D-ED133471E84D

P698

Q36680199-95F83AF2-9B1F-4870-B5DF-5705257A7FC3

P921

Q36680199-5B8077CE-084C-4711-BC6D-AB967CC61303

Q36680199-BCF789AD-A9C1-4A9C-A8B4-F847DEDB83F2

P932

Q36680199-2E121B6F-D194-4A73-B21B-7E22BEAF7408

P356

1078-0432.CCR-12-2442

P1433

Clinical Cancer Research

P1476

Phase I and pharmacologic tria ...... in refractory acute leukemias

@en

P2093

B Douglas Smith

http://www.w3.org/2001/XMLSchema#string

Brian M Thomas

http://www.w3.org/2001/XMLSchema#string

Christopher Sorge

http://www.w3.org/2001/XMLSchema#string

David A Parry

http://www.w3.org/2001/XMLSchema#string

Douglas E Gladstone

http://www.w3.org/2001/XMLSchema#string

Hetty E Carraway

http://www.w3.org/2001/XMLSchema#string

Jacqueline M Greer

http://www.w3.org/2001/XMLSchema#string

Jo Ann Horowitz

http://www.w3.org/2001/XMLSchema#string

Judith E Karp

http://www.w3.org/2001/XMLSchema#string

Karen Mackey

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing

Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints.

ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1

Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Chk1 is essential for tumor cell viability following activation of the replication checkpoint.

New insights into checkpoint kinase 1 in the DNA damage response signaling network.

Cytarabine dose for acute myeloid leukemia.

Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases.

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.

P304

6723-6731

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-2442

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Scott H Kaufmann

P577

2012-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23092873

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3596113

http://www.w3.org/2001/XMLSchema#string